6MO Single-cell analysis of peripheral blood mononuclear cells reveals therapy outcomes are associated with pre-existing immunity in patients treated with oncolytic adenovirus armed with TNFα and IL2

Engineered oncolytic adenovirus Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123) has emerged as a promising candidate for clinical translation due to its ability to induce tumor regression and activate host immunity. The phase 1 clinical trial TUNIMO (NCT04695327) assessed the safety of TILT-123 in patients with advanced solid tumors and provided important insights into its therapeutic activity. The presented study aimed to identify immunological markers in peripheral blood capable of predicting treatment outcomes and to elucidate the mechanisms through which TILT-123 modulates immune responses in patients.

Authors

Institutions

Publication Details

Journal
Immuno-Oncology Technology
Published
2024-12-01
DOI
https://doi.org/10.1016/j.iotech.2024.100890
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

6MO Single-cell analysis of peripheral blood mononuclear cells reveals therapy outcomes are associated with pre-existing immunity in patients treated with oncolytic adenovirus armed with TNFα and IL2

Santeri A. Pakola, K. Jalkanen, J. Clubb, L. Haybout et al.
Immuno-Oncology Technology
Virus-based gene therapy research
article

6MO Single-cell analysis of peripheral blood mononuclear cells reveals therapy outcomes are associated with pre-existing immunity in patients treated with oncolytic adenovirus armed with TNFα and IL2

Santeri A. Pakola, K. Jalkanen, J. Clubb, L. Haybout, Elise Jirovec, Tatiana V. Kudling, Riikka Havunen, Victor Arias, A. Hemminki, A. Kanerva, C. Kistler, Dmitrii Bychkov, Tuomo Alanko, João M. Santos, S. Sorsa, Víctor Cervera-Carrascón, Otto Hemminki, D.C.A. Quixabeira, M. van der Heijden, Nea Ojala
article en

Abstract

Engineered oncolytic adenovirus Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123) has emerged as a promising candidate for clinical translation due to its ability to induce tumor regression and activate host immunity. The phase 1 clinical trial TUNIMO (NCT04695327) assessed the safety of TILT-123 in patients with advanced solid tumors and provided important insights into its therapeutic activity. The presented study aimed to identify immunological markers in peripheral blood capable of predicting treatment outcomes and to elucidate the mechanisms through which TILT-123 modulates immune responses in patients.

Immuno-Oncology TechnologyVol. 24
University of Helsinki (FI), Helsinki University Hospital (FI), Oxford Biotherapeutics (United Kingdom) (GB), Institute for Molecular Medicine Finland (FI), Docrates Cancer Center (FI)
Ida Montinin Säätiö, Helsingin Yliopisto, Punainen Risti Veripalvelu, Jane ja Aatos Erkon Säätiö, Sigrid Juséliuksen Säätiö, Syöpäsäätiö, Horizon 2020, H2020 Marie Skłodowska-Curie Actions
Openalex Percentile: Top 74%
Virus-based gene therapy research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.